Posted by ABMN Staff on Apr 19th, 2024
Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by equities research analysts at Wedbush from $245.00 to $213.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The...
More of this article »